Dr. Mathew was part of the founding team of BioLife Solutions, Inc., and is a co-developer of BioLife’s biopreservation media solutions. He is a co-inventor on multiple issued and pending patents related to methods, devices, and formulations for the preservation of cells, tissues, and organs. He holds a Ph.D. in Biological Sciences within the Biochemistry, Cell and Molecular Biology Program from Binghamton University and a B.S. in Microbiology from Cornell University. Dr. Mathew has been researching low temperature biopreservation since 1994, and his studies contributed to the development of BioLife’s current commercial HypoThermosol® and CryoStor® product platforms and intellectual property foundation. Dr. Mathew was part of the scientific team that linked cell death via apoptosis (programmed cell death) to exposure to hypothermic and/or freezing temperatures. These discoveries were integral to the development of BioLife’s intracellular-like biopreservation media, and also contributed to improvements in cryosurgical ablation of cancer. Dr. Mathew was BioLife’s first Director of Manufacturing, established BioLife’s initial Quality system, and has been Executive Vice President & Chief Scientific Officer since December 2019. From February 2011 through November 2019, Dr. Mathew served as Senior Vice President & Chief Technology Officer. From January 2007 through February 2011, Dr. Mathew served as Senior Scientist, Director of Strategic Relations, and Senior Director of Strategic Relations. From June 2003 through January 2007, Dr. Mathew served as Director of Manufacturing. From September 2000 through June 2003, Dr. Mathew served as Clinical Accounts Manager and Director of Hypothermic Preservation for Cryomedical Sciences/BioLife Solutions. Dr. Mathew is currently active in, or previously a member of, AABB (formerly the American Association of Blood Banks), BEST (the Biomedical Excellence for Safer Transfusion collaborative), the International Society for Cell and Gene Therapy (ISCT), the Alliance for Regenerative Medicine (ARM), Tissue Engineering & Regenerative Medicine International Society (TERMIS), Society for Cryobiology, International Society for Biological and Environmental Repositories (ISBER), American Society for Cell Biology, and the Society for In Vitro Biology. Dr. Mathew is a member of: the Board of Directors, and Advisory Panel, of the Parent’s Guide to Cord Blood Foundation, the Scientific Advisory Board of HemaCare Corporation, the founding Board of Directors of the Cord Blood Association, the NIST-AMTech National Cell Manufacturing Consortium, the California Institute for Regenerative Medicine (CIRM) Clinical Advisory Panel, the Business Advisory Board of RoosterBio Inc., and the Scientific Advisory Board of SAVSU Technologies. Dr. Mathew has obtained UCLA Corporate Governance Program Certification
What is Aby J. Mathew's net worth?
The estimated net worth of Aby J. Mathew is at least $7.47 million as of November 26th, 2024. Dr. Mathew owns 283,919 shares of BioLife Solutions stock worth more than $7,472,748 as of December 11th. This net worth estimate does not reflect any other assets that Dr. Mathew may own. Additionally, Dr. Mathew receives a salary of $448,200.00 as VP at BioLife Solutions. Learn More about Aby J. Mathew's net worth.
How old is Aby J. Mathew?
Dr. Mathew is currently 52 years old. There are 6 older executives and no younger executives at BioLife Solutions. The oldest executive at BioLife Solutions is Mr. Roderick de Greef, CEO & Chairman, who is 64 years old. Learn More on Aby J. Mathew's age.
What is Aby J. Mathew's salary?
As the VP of BioLife Solutions, Inc., Dr. Mathew earns $448,200.00 per year. There are 2 executives that earn more than Dr. Mathew. The highest earning executive at BioLife Solutions is Mr. Roderick de Greef, CEO & Chairman, who commands a salary of $1,630,000.00 per year. Learn More on Aby J. Mathew's salary.
How do I contact Aby J. Mathew?
Has Aby J. Mathew been buying or selling shares of BioLife Solutions?
During the last quarter, Aby J. Mathew has sold $1,145,138.67 in shares of BioLife Solutions stock. Most recently, Aby J. Mathew sold 523 shares of the business's stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $27.20, for a transaction totalling $14,225.60. Following the completion of the sale, the executive vice president now directly owns 283,919 shares of the company's stock, valued at $7,722,596.80. Learn More on Aby J. Mathew's trading history.
Who are BioLife Solutions' active insiders?
Are insiders buying or selling shares of BioLife Solutions?
In the last twelve months, insiders at the medical equipment provider sold shares 74 times. They sold a total of 135,966 shares worth more than $2,718,539.10. The most recent insider tranaction occured on November, 26th when CFO Troy Wichterman sold 581 shares worth more than $15,803.20. Insiders at BioLife Solutions own 2.2% of the company.
Learn More about insider trades at BioLife Solutions. Information on this page was last updated on 11/26/2024.